RecruitingRecurrent Group 3 MedulloblastomaRecurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

Eligible age

4–30 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a pilot study in a small number of children and young adults with suspected recurrent/progressive medulloblastoma (MB) looking at the feasibility and safety of adoptive cell therapy plus PD-1 blockade.

Sponsor: University of Florida

You may qualify if…

✓ 1. Children and young adults ages 4-30 years with suspected recurrence/progression of Group 3 or 4 (non-SHH/non-WNT) MB since completion of definitive focal +/- craniospinal irradiation who are a candidate for surgical resection or biopsy. Of the 6 evaluable subjects, a minimum of 3 slots must be reserved for patients with confirmed Group 4 MB. Patients who are unable to receive radiation therapy due to genetic disorders that put them at significant risk for radiation-induced secondary malignancies (i.e. Gorlin's syndrome or NF1 mutation) are eligible for enrollment at first disease recurrence/progression.
✓ 2. Patients must currently be prescribed and approved to receive pembrolizumab therapy (patients who have progressed on anti-PD-1 targeting therapy but are otherwise eligible may be enrolled to receive combination with immunotherapy. Patients who have been previously treated with anti-PD-1 targeting therapy alone or in combination with other agents and discontinued for reasons other than toxicity may be enrolled).
✓ 3. Must be a candidate for surgery/biopsy Or tumor tissue obtained clinically, has been previously stored in a qualified biorepository suitable for tumor RNA extraction and amplification and sample is made available to the PI.
✓ 4. Karnofsky or Lansky Performance Status (KPS) ≥ 60% (KPS for \> 16 years of age) or Lansky performance Score (LPS) of ≥ 60 (LPS for \< 16 years of age)
✓ 5. Adequate bone marrow and organ function as defined below:
✓ ANC ≥ 1,000/mcL (unsupported)
✓ Platelets ≥ 100,000/mcL (unsupported for at least 3 days)
✓ Hemoglobin ≥ 9 g/dL (may be supported)

You may not qualify if…

✕ this study:
✕ 1. Prior discontinuation of PD-1 inhibitor treatment due to toxicity.
✕ 2. Corticosteroids equivalent to ≥ 4mg dexamethasone daily.
✕ 3. Known HIV, Hepatitis B, or Hepatitis C seropositive.
✕ 4. Known active infection or immunosuppressive disease.
✕ 5. Known autoimmune disease requiring medical management with immunosuppressant.
✕ 6. Pregnancy or lactation, due to possible adverse effects on the developing fetus or infant.
✕ 7. Treatment with another investigational drug or other intervention within 30 days prior to projected first dose of study treatment (Priming phase with TTRNA-DC).

Where it's recruiting

Florida

Gainesville

Source: ClinicalTrials.gov · NCT06514898 · last updated 2026-06-10